Global HIV diagnosis and treatment Market Size To Reach $66.3 Billion By 2035

Global HIV diagnosis and treatment market is projected to grow from $39.5 billion in 2025 and is projected to reach $66.3 billion by 2035, growing at a CAGR of 5.3% during the forecast period 2026-2035. The global HIV diagnosis and treatment market is shaped by sustained demand for effective therapeutic regimens and reliable diagnostic solutions. A gradual transition toward long-acting treatment options is influencing prescribing patterns, as these formulations reduce dosing frequency and support adherence. At the same time, combination therapies continue to be widely adopted due to their ability to simplify treatment protocols. On the diagnostic side, advancements in molecular testing and point-of-care technologies are improving early detection and monitoring capabilities. Increased emphasis on routine screening and timely diagnosis is further strengthening demand for testing products. In addition, ongoing efforts to expand access to care in developing regions are contributing to broader product utilization.

Browse the full report description of “HIV Diagnosis and Treatment Market Size, Share & Trends Analysis by Product Type (Diagnostic Tests and Antiretroviral Therapy (ART) Drugs), by Diagnostic Type (Screening Tests, Confirmatory Tests, Monitoring Tests, and Specialized Diagnostic Tests), by Route of Administration (Oral and Injectable), by End-Users (Hospitals, Diagnostic Laboratories, Home Care Settings, and Specialty Clinics), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/hiv-diagnosis-and-treatment-market

Another important trend in the market is the growing role of generic drug manufacturers in improving treatment accessibility across cost-sensitive regions. The availability of affordable antiretroviral drugs has enabled wider patient coverage, particularly in regions with high disease burden. Meanwhile, diagnostic manufacturers are focusing on enhancing test accuracy and reducing turnaround times to support clinical decision-making. The integration of decentralized testing approaches is also gaining attention, especially in areas with limited laboratory infrastructure. Furthermore, collaborations between public health organizations and private companies are supporting the distribution of both diagnostic and treatment products. These combined factors continue to drive steady development across the global market.

Competitive Landscape of the HIV diagnosis and treatment Market

The key players in the HIV diagnosis and treatment market are Gilead Sciences Inc., ViiV Healthcare Ltd., Merck & Co Inc., Johnson & Johnson, and Abbott Laboratories, among others. These companies maintain a strong presence through extensive portfolios covering both therapeutic and diagnostic offerings, supported by continuous product development and lifecycle management strategies. Their focus remains on improving treatment adherence, expanding access across diverse regions, and enhancing diagnostic accuracy. Competitive positioning is influenced by innovation in long-acting therapies and advanced testing technologies. In addition, strategic collaborations and distribution networks enable broader market reach and sustained product availability.

• In July 2025, Merck announced that it would present new research findings from its HIV prevention and treatment pipeline at the International AIDS Society (IAS 2025) conference. This included data on an investigational oral once?monthly compound intended for HIV prevention (PrEP) and safety/pharmacokinetic findings from its broader clinical programs, illustrating the company’s ongoing development efforts in both treatment and prevention areas.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Diagnostic Type
  • By Route of Administration
  • By End-Users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Gilead Sciences Inc., ViiV Healthcare Ltd., Merck & Co Inc., Johnson & Johnson, and Abbott Laboratories, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global HIV diagnosis and treatment Market Report Segment

By Product Type

• Diagnostic Tests
• Antiretroviral Therapy (ART) Drugs

By Diagnostic Type

• Screening Tests
• Confirmatory Tests
• Monitoring Tests
• Specialized Diagnostic Tests

By Route of Administration

• Oral
• Injectable

By End-Users

• Hospitals
• Diagnostic Laboratories
• Home Care Settings
• Specialty Clinics

Global HIV diagnosis and treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hiv-diagnosis-and-treatment-market